ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients

J Infect Dis. 2023 Aug 31;228(Suppl 2):S77-S82. doi: 10.1093/infdis/jiad246.

ACTIV-2/A5401 Study Team:
Lara Hosey, Jhoanna Roa, Nilam Patel, Frontier Science, Bill Erhardt, Lorraine Waring, Diane Hessinger, Stacey Adams

¹ Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, USA.
² Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
³ Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
⁴ Department of Medicine, University of California, San Diego, La Jolla, California, USA.
⁵ Division of AIDS, National Institutes of Health, Rockville, Maryland, USA.
⁶ Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, USA.

Abstract

Clinical Trials Registration ClinicalTrials.gov Identifier: NCT04518410.

Keywords: ACTIV-2; COVID-19; clinical trial; monoclonal antibodies.